News Conference News ESC 2024 New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower Yael L. Maxwell September 04, 2024
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Daily News Sham Procedures in CV Research: What’s Sacrificed for Science? Caitlin E. Cox October 23, 2023
News Daily News As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions L.A. McKeown August 18, 2023
News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2022 Shelley Wood October 03, 2022
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Daily News Renal Denervation a Third Option for Hypertension, European Experts Say Todd Neale September 17, 2021
News Conference News ACC 2021 Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO Michael O'Riordan May 16, 2021
News Daily News FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies Michael O'Riordan December 06, 2018
News Conference News EuroPCR 2018 EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage Shelley Wood May 17, 2018
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Daily News FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints Michael O'Riordan August 16, 2017